Trisomy 21 and Congenital Heart Disease: Impact on Health and Functional Outcomes From Birth Through Adolescence: A Scientific Statement From the American Heart Association
- PMID: 39263820
- PMCID: PMC11681493
- DOI: 10.1161/JAHA.124.036214
Trisomy 21 and Congenital Heart Disease: Impact on Health and Functional Outcomes From Birth Through Adolescence: A Scientific Statement From the American Heart Association
Abstract
Due to improvements in recognition and management of their multisystem disease, the long-term survival of infants, children, and adolescents with trisomy 21 and congenital heart disease now matches children with congenital heart disease and no genetic condition in many scenarios. Although this improved survival is a triumph, individuals with trisomy 21 and congenital heart disease have unique and complex care needs in the domains of physical, developmental, and psychosocial health, which affect functional status and quality of life. Pulmonary hypertension and single ventricle heart disease are 2 known cardiovascular conditions that reduce life expectancy in individuals with trisomy 21. Multisystem involvement with respiratory, endocrine, gastrointestinal, hematological, neurological, and sensory systems can interact with cardiovascular health concerns to amplify adverse effects. Neurodevelopmental, psychological, and functional challenges can also affect quality of life. A highly coordinated interdisciplinary care team model, or medical home, can help address these complex and interactive conditions from infancy through the transition to adult care settings. The purpose of this Scientific Statement is to identify ongoing cardiovascular and multisystem, developmental, and psychosocial health concerns for children with trisomy 21 and congenital heart disease from birth through adolescence and to provide a framework for monitoring and management to optimize quality of life and functional status.
Keywords: AHA Scientific Statements; Down syndrome; autism spectrum disorder; cognition; heart defects, congenital; mental health; quality of life.
Conflict of interest statement
Writing Group Disclosures
[Table: see text]
Reviewer Disclosures
[Table: see text]
Figures


References
-
- Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S, Priest JR, Pu WT, Roberts A, et al. Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association. Circulation. 2018;138:e653–e711. doi: 10.1161/CIR.0000000000000606 - DOI - PMC - PubMed
-
- Sood E, Newburger JW, Anixt JS, Cassidy AR, Jackson JL, Jonas RA, Lisanti AJ, Lopez KN, Peyvandi S, Marino BS, et al. Neurodevelopmental outcomes for individuals with congenital heart disease: updates in neuroprotection, risk‐stratification, evaluation, and management: a scientific statement from the American Heart Association. Circulation. 2024;149:e997–e1022. doi: 10.1161/CIR.0000000000001211 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical